Sie suchten nach: effector (Englisch - Maltesisch)

a separator can be a space character or format effector.
separatur jista' jkun karattru ta' spazju jew effettur ta' format.

16 the fab domain of rituximab binds to the cd20 antigen on b lymphocytes and the fc domain can recruit immune effector functions to mediate b cell lysis.
l- arja fab tar- rituximab torbot ma ’ l- antiġen cd20 fuq limfositi b u l- arja fc tkun tista ’ tqabbad funzjonijiet li jaffetwaw l- immunità sabiex iservu ta ’ medjaturi fil- lisi taċ- ċellula b.

such medicinal products, if used concomitantly with lonsurf, may compete with the effector, trifluridine, for activation via thymidine kinases.
prodotti mediċinali bħal dawn, jekk użati b’mod konkomitanti ma’ lonsurf, jistgħu jikkompetu mal-effettur, trifluridine, għall-attivazzjoni permezz ta’ thymidine kinases.

approximately 15-20% of t lymphocytes have an effector memory phenotype, cells that are important for peripheral immune surveillance.
madwar 15-20% tal- limfoċiti t għandhom memorja b’fenotip effetturi, ċelloli li huma importanti fil-ħarsien tas-sistema immuni periferali.

antimuscarinics are competitive inhibitors of the actions of acetylcholine at the muscarinic receptors of autonomic effector sites innervated by parasympathetic (cholinergic postganglionic) nerves.
l-antimuskariniċi huma inibituri kompetittivi tal-azzjonijiet tal-aċetilkolina fir-riċetturi muskariniċi tas-siti tal-effettur awtonomiku innervati min-nervituri parasimpatiċi (postganglijoniċi kolinerġiċi).

it is thought that together with gm-csf, it will promote a systemic anti- tumour immune response and an effector t-cell response.
hu maħsub li flimkien ma’ gm-csf, jippromwovi rispons immuni sistematiku kontra t-tumur u jaffettwa r-rispons taċ-ċellola-t.

cetuximab also targets cytotoxic immune effector cells towards egfr- expressing tumour cells (antibody dependent cell-mediated cytotoxicity, adcc).
cetuximab għandu fil-mira wkoll iċ-ċelluli effector immuni ċitotossiċi lejn ċelluli tat-tumur li jesprimu egfr (antibody dependent cell-mediated cytotoxicity, adcc).

in a study of 49 adult patients with rheumatoid arthritis treated with enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations.
fi studju fuq 49 pazjent adult bl-artrite rewmatojde li ngħataw enbrel, ma nstabet l-ebda evidenza ta’ tnaqqis ta’ sensittività eċċessiva tat-tip li jittardja, ta’ tnaqqis tal-livelli ta’ l-immunoglobina, jew tibdil fl-enumerazzjoni tal-popolazzjonijiet taċ-ċelluli effector.

in a study of 64 patients with rheumatoid arthritis that were treated with humira, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector t-, b, - nk-cells, monocyte/macrophages, and neutrophils.
fi studju ta’ 64 pazjent li jbatu minn artrite rewmatika li kienu kkurati b’humira, ma kien hemm l- ebda evidenza ta’ tnaqqis ta’ sensitività eċċessiva imdewma, tnaqqis tal-livelli ta’ immunoglobuli, jew tibdil fin-numri ta’ ċelloli effettivi t-, b-, nk-, monoċistiċi /makrofaġi, u newtrofili.